( MIAMI--(BUSINESS WIRE)--Jun 21 2007 - ...)Answerthink and LORENZ Life Sciences Group Announce Strategic,Alliance for the SAP Life Science Industry,Health

MIAMI--(BUSINESS WIRE)--Jun 21, 2007 - Answerthink, Inc. (NASDAQ: ANSR) announced today that it has formed a strategic alliance with LORENZ Life Sciences Group for the distribution of LORENZ solutions in North America. Answerthink and LORENZ Life Sciences Group will serve midsize companies by integrating best practice submissions management solutions into Answerthink's Life Science solutions based on SAP technology.

Answerthink's pre-configured EzLifeSciences solutions are designed specifically to help midsize companies streamline new product development, automate manufacture reporting, and meet regulatory compliance requirements. LORENZ's solutions are geared specifically for submission assembly, review, publishing, validation and management for regulated environments within the life sciences industry as well as supporting the FDA mandate to submit electronically by the end of 2007.

"We are delighted to be able to tap into Answerthink's North American sales and service infrastructure, as well as their unrivaled SAP solution and deployment knowledge in the Life Sciences industry," said Wolfgang Witzel, President of LORENZ Life Sciences Group.

"This is a welcome confirmation of the global reputation we have acquired since 1989 in the field of submission management," added Mr. Witzel, stating that "the solutions we have provided to our customers and the results they have achieved are indeed - best practice."

According to Answerthink SAP Solutions Group Managing Director John McGrath, "We're delighted to be working with LORENZ. Our EzLifeSciences solutions are providing superior value for growing, innovative customers. LORENZ has successfully developed purpose-built solutions that can be integrated at ease which will only enhance our offerings to this industry."

About Answerthink

Answerthink, Inc. (www.answerthink.com) is a leading business and technology consulting firm that ena
'"/>

Page: 1 2 3
Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
7. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
10. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
11. IR BioSciences Announces Promising Data from Study of Its Compound Homspera